HSY244 / Novartis 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HSY244 / Novartis
NCT04582409: A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

Terminated
2
13
Europe, US
HSY244, Placebo
Novartis Pharmaceuticals
Atrial Fibrillation
07/22
07/22
2020-004327-17: Study with HSY244 to restore normal heart rhythm in people with atrial fibrillation

Not yet recruiting
2
80
Europe
HSY244, HSY244, Concentrate for solution for injection
Novartis Pharma AG, Novartis Pharma AG
Atrial Fibrillation, An abnormal and irregular heart rhythm in which electrical signals are generated chaotically throughout the upper chambers of the heart., Diseases [C] - Cardiovascular Diseases [C14]
 
 

Download Options